Anixa Biosciences Inc
Anixa Biosciences develops liraltagene autoleucel, a CAR-T cell therapy targeting FSHR for recurrent ovarian cancer.
10-QSep 9Latest SEC filing, period to Jul 31
Jul 17Latest story
July 2026
Sign inSign inAnixa Biosciences develops liraltagene autoleucel, a CAR-T cell therapy targeting FSHR for recurrent ovarian cancer.